secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2026-08-18T13:03:53+00:00
Accession:  0001193125-26-354793
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amylyx announces positive topline Phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia
--------------------------------------------------------------------------------

- Positive topline results announced Aug 18, 2026 from LUCIDITY Phase 3 trial of avexitide in post-bariatric hypoglycemia (PBH).
- Trial enrolled participants with PBH following Roux-en-Y gastric bypass surgery; no efficacy numbers disclosed in filing text.
- Investor conference call and slide deck (Exhibit 99.1) held same day; detailed endpoint data not included in available excerpt.
- Avexitide is Amylyx's (AMLX) candidate for PBH; positive readout could support registration pathway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000119312526354793/0001193125-26-354793-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000119312526354793/d184004d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-354793

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer